Abstract: AIM: To compare the efficacy of rabeprazole-based triple therapy in the treatment of helicobacter pylori (H.pylori)-positive patient with portal hypertension gastric disease (PHG).METHODS: We selected 62 consecutive H.pylori positive patients with portal hypertension gastric disease and randomized them into 2 Chin J Clin Pharmacol Ther 2006 Dec;11(12) groups.The RFA grouPwas treated with rabeprazole 10 mg bid (rabeprazole-group, n =32), and the OFA grouPwas treated with omeprazole 20 mg bid (omeprazolegroup,n =30) for 1 week, all patients were given amoxicillin 1 g bid and furazolidone 100 mg bid for one week meawhile.One month after treatment, the eradication rate of H.pylori was valuated according to result of C¹⁴ureabreath test and helicobacter pylori stool antigen.RESULTS: The eradication rate of H.pylori for patients in RFA grouPand OFA grouPwere 81.3 % % vs 73.3 % by intention to treat analysis and 89.7 % vs 81.5 % by per protocol (P>0.05).Few major severe adverse events were reported.The mild-moderate side effect rate in RFA grouPand OFA grouPwere 28.1 % and 53.3 %,respectively (P<0.05).The levels of serum total bilirubin(STB) and alanine aminotransferase (ALT) after treatment were significantly higher than that before treatment in OFA group.The significant increases of STB and ALT after treatment had not found in RFA group.CONCLUSION: For the patients with portal hypertension gastric disease, there is no significant difference between the two groups in terms of the eradication rate of H.pylori(P>0.05), but RFA grouPis obviously lower than the OFA grouPin the side-effect of drugs, so it is an ideal therapy.

Key words: rabeprazole, helicobacter pylori, efficacy